Day One Biopharmaceuticals shares jumped 26.7% in the latest session on trading volume more than 50% above its 30-day average, driven by renewed investor interest following the company’s preliminary revenue update and conference presentation. Despite the sharp uptick, consensus earnings revisions over the past month have shown only marginal upgrades, with 2026 per-share forecasts nudged higher by just 2% and 2027 estimates unchanged. This divergence suggests that while sentiment has improved in the near term, analysts remain cautious about sustainable profit growth until additional clinical readouts materialize.

Preliminary results show OJEMDA™ net product revenue of $155.4 million for full-year 2025, a 172% increase versus 2024, including $52.8 million in the fourth quarter alone, up 37% quarter-over-quarter. Prescription volumes rose to 1,394 scripts in Q4, reflecting strong uptake in relapsed or refractory pediatric low-grade glioma. Management now projects 2026 U.S. OJEMDA revenue between $225 million and $250 million, implying mid-point growth of 53% year-over-year, supported by persistency initiatives and new patient starts.

As of December 31, 2025, Day One held approximately $441.1 million in cash, cash equivalents and short-term investments, providing runway through key milestones. The company highlighted upcoming data events at the J.P. Morgan Healthcare Conference, including mid-2026 Phase 1 results for Emi-Le (emiltatug ledadotin) and H2 2026 initial Phase 1a data for DAY301. Completion of enrollment in the pivotal FIREFLY-2 Phase 3 trial for first-line pLGG is expected in the first half of 2026, setting the stage for a mid-2027 data readout and potential 2028 approval.